Discounted Registration: Buprenorphine Treatment for Opioid Use Disorder | CAMH

In an effort to encourage increased capacity for high-quality care for persons with opioid use disorder in primary care, the Division of Mental Health and Addiction has partnered with CAMH to offer a 50% discount in fees for the highly reviewed Buprenorphine Treatment for Opioid Use Disorder course.

This 6-8-week online course aims to present a framework for providing maintenance treatment for opioid use disorder with buprenorphine, including its use in a primary care setting. There is still room for enrollment for this year’s cohort.

The course walks the learner through the key elements of selecting, preparing, initiating, and maintaining a patient with opioid use disorder on buprenorphine treatment.

Learning objectives include outlining the evidence supporting buprenorphine as a first-line opioid agonist for opioid use disorder treatment, diagnosing patients for opioid use disorder based on DSM-5 criteria, and determining the best evidence-based treatment course for the patient’s context and values.

• Intended audience: Frontline clinicians who provide treatment for opioid use disorder
• Prerequisites: None
• Dates: October 1, 2024 - August 31, 2025 [STILL OPEN FOR ENROLLMENT!]
• Delivery: Online, self-paced
• Cost for DFCM faculty: $212.50 (reduced rate). $106 for residents.

For discounted registration for faculty: Register here

For discounted registration for learners: Register here

*Please note, registration for DFCM faculty and residents is ongoing.

This course is accredited for:

• The College of Family Physicians of Canada: 13.5 Mainpro+ credits
• The Royal College of Physicians and Surgeons: 13.5 Section 1 hours